Form 4: Oramed CFO Gabay Boosts Equity Holdings with New Awards

Oramed Pharmaceuticals' CFO Avraham Gabay reported significant equity awards, including Restricted Stock Units and Performance Stock Units, increasing his beneficial ownership.

Summary

• Avraham Gabay, Chief Financial Officer of Oramed Pharmaceuticals Inc. (ORMP), reported the acquisition of 81,216 Restricted Stock Units (RSUs) on December 31, 2025, which vested in full on January 1, 2026.
• An additional 115,000 RSUs were acquired on December 31, 2025, set to vest in quarterly installments over a three-year period starting January 1, 2026.
• Gabay also acquired 19,000 Performance Stock Units (PSUs) on December 31, 2025, which vest upon the achievement of a specified stock price or applicable performance criteria.
• Following these transactions, Gabay's direct beneficial ownership of common stock increased to 630,256 shares, and he holds 19,000 PSUs.
• Each RSU and PSU represents the right to receive one share of Oramed's common stock.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive as it indicates increased insider ownership and long-term incentive alignment for a key executive, which is generally viewed favorably by investors. However, it's a routine compensation event rather than a direct cash investment, tempering the positivity.

Positives

• Increased insider ownership by the Chief Financial Officer, aligning management interests with shareholders.
• The awards include performance-based units (PSUs), incentivizing the CFO to achieve specific company performance or stock price targets.
• A significant portion of the awards (115,000 RSUs) vests over a three-year period, indicating a long-term commitment from the CFO.

Negatives

• The transactions represent equity awards rather than open market purchases, meaning no direct cash investment by the CFO at the time of grant.
• A substantial portion of the awards are subject to future vesting conditions, meaning the full benefit is not immediately realized.

Risks

• NA

Future Outlook

The future outlook includes the vesting of 115,000 RSUs in quarterly installments over a three-year period starting January 1, 2026, and the vesting of 19,000 PSUs upon the achievement of specified stock price or performance criteria.

Industry Context

This filing reflects a routine executive compensation event within the pharmaceutical industry, where equity awards like RSUs and PSUs are common tools to incentivize and retain key management personnel, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and Performance Stock Units (PSUs) for executive compensation is a standard practice across the biotechnology and pharmaceutical sectors, comparable to compensation structures at companies like Pfizer, Moderna, or Johnson & Johnson, which frequently utilize equity-based incentives to attract and retain top talent.
• The vesting schedules, including immediate vesting for some RSUs and multi-year vesting for others, are typical for executive compensation packages, designed to encourage long-term commitment and performance.

Stakeholder Impact

• Shareholders: Potential positive impact due to increased alignment of the CFO's interests with long-term company performance and shareholder value through equity awards.
• Employees: No direct impact mentioned, but executive compensation practices can influence overall company culture and compensation strategies.

Next Steps

• Continued vesting of 115,000 RSUs in quarterly installments over the next three years, starting January 1, 2026.
• Monitoring for the achievement of specified stock price or performance criteria for the 19,000 PSUs to vest.

Key Dates

Recommendation

This Form 4 filing details routine equity compensation for a key executive and does not present new information that would fundamentally alter the investment thesis for Oramed Pharmaceuticals. While increased insider ownership is generally positive, these are awards rather than open market purchases, and thus do not warrant a change in recommendation based solely on this filing.

Keywords

Oramed Pharmaceuticals, ORMP, Avraham Gabay, Chief Financial Officer, CFO, SEC Form 4, Insider Ownership, Restricted Stock Units, RSUs, Performance Stock Units, PSUs, Equity Awards, Beneficial Ownership, Stock Compensation